Last reviewed · How we verify
Metfomin
At a glance
| Generic name | Metfomin |
|---|---|
| Sponsor | Cairo University |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Comparative Evaluation of Topical Metformin and Topical Tranexamic Acid in Melasma (NA)
- The Role of CYP8B1 Polymorphisms in Modulating the Biochemical Pathways Affected by SGLT2 Inhibitors in T2DM and Obesity (PHASE4)
- The Efficacy and Safety of Metformin Intervention in Elderly Overweight or Obesity With Mild Cognitive Impairment (PHASE1, PHASE2)
- Effect of Metformin on Endometrial Thickness in Postmenopausal Breast Cancer Patients Receiving Tamoxifen (NA)
- Anti-Diabetic Drug, Exercise and Healthy Diet for Knee Osteoarthritis With Overweight/Obesity (EARLY_PHASE1)
- The Combined Effect of N-Acetyl Cysteine and Metformin in Polycystic Ovary Syndrome Patients (PHASE3)
- Fetal Hemoglobin Induction Treatment Metformin (EARLY_PHASE1)
- Metformin Versus Vildagliptin in Reducing Risk of Metabolic Syndrome Complications Progression (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Metfomin CI brief — competitive landscape report
- Metfomin updates RSS · CI watch RSS
- Cairo University portfolio CI